Progyny director amends sale price on 11.5K shares
Progyny, Inc. (PGNY) director Kevin K. Gordon reported an option exercise and related share dispositions on September 10, 2026.
Rhea-AI Filing Summary
Progyny, Inc. (PGNY) director Kevin K. Gordon reported an option exercise and related share dispositions on September 10, 2026. He exercised stock options for 22,000 shares of common stock at an exercise price of $13.00 per share, from fully vested options expiring October 11, 2029. Of the resulting shares, 10,500 shares were delivered or withheld at $27.24 per share to pay the option exercise price or related tax liability, and 11,500 shares were sold at a weighted average price of $27.1181 per share in multiple trades between $26.99 and $27.24. This Form 4/A amends a prior filing solely to correct the previously reported weighted average sale price, which was originally stated as $27.9442.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
GORDON KEVIN K
Role
Director
Sold
11,500 shs ($312K)
Approx. gross sale proceeds
$312K
Approx. exercise cost
$286K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F3 | 22,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 22,000 | $13.00 | $286K |
| Exercise Price or Tax Liability | Common Stock | 10,500 | $27.24 | $286K |
| Sale | Common Stock F1, F2 | 11,500 | $27.1181 | $312K |
Holdings After Transaction:
Stock Option (Right to Buy) — 22,000 contracts (Direct);
Common Stock — 6,792 shares (Direct)
Footnotes (3)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.99 to $27.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- F2. This Form 4 is being filed to correct a clerical error in a previously filed Form 4. The weighted average for the transaction was inadvertently reported as $27.9442 instead of $27.1181. All other information previously reported remains unchanged.
- F3. The shares are fully vested.
Key Figures
Options exercised: 22,000 shares
Option exercise price: $13.00 per share
Shares withheld or delivered: 10,500 shares
+5 more
8 metrics
Options exercised
22,000 shares
Stock options exercised into common stock on September 10, 2026
Option exercise price
$13.00 per share
Exercise price for 22,000 stock options exercised
Shares withheld or delivered
10,500 shares
Delivered or withheld to pay exercise price or tax liability
Share price for withholding
$27.24 per share
Price used for 10,500 shares delivered or withheld
Shares sold
11,500 shares
Common stock sold on September 10, 2026
Corrected weighted average sale price
$27.1181 per share
Weighted average for 11,500 shares sold, correcting prior $27.9442
Sale price range
$26.99–$27.24 per share
Price range for multiple sale transactions included in the weighted average
Option expiration date
October 11, 2029
Expiration date of exercised stock options
Key Terms
weighted average price, Form 4, stock option, tax liability, +1 more
5 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Form 4 regulatory
"This Form 4 is being filed to correct a clerical error"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
stock option financial
"Stock Option (Right to Buy)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
tax liability financial
"Payment of exercise price or tax liability by delivering or withholding securities"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Progyny (PGNY) director Kevin K. Gordon report?
Kevin K. Gordon reported exercising stock options for 22,000 shares of Progyny common stock at an exercise price of $13.00 per share on September 10, 2026, then disposing of the resulting shares through a combination of share withholding and open-market sales.
How many Progyny (PGNY) options did Kevin K. Gordon exercise and at what price?
He exercised stock options covering 22,000 shares of Progyny common stock at an exercise price of $13.00 per share. The options were fully vested and carried an expiration date of October 11, 2029.
What correction does this Form 4/A make for Progyny (PGNY)?
The amendment corrects a clerical error in the previously reported weighted average sale price. The correct weighted average is $27.1181 per share, which had been inadvertently reported earlier as $27.9442 per share. All other previously reported information remains unchanged.
Were Progyny (PGNY) insider trades by Kevin K. Gordon under a Rule 10b5-1 plan?
No. The filing indicates that the Rule 10b5-1 trading plan checkbox is not selected, and there is no footnote stating that the transactions were made pursuant to a Rule 10b5-1 or similar pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
